Revertant mosaicism in fanconi anemia

Natural gene therapy at work

H. Hoehn, R. Kalb, K. Neveling, R. Friedl, A. Bechtold, S. Herterich, Y. Sun, B. Gruhn, H. Hanenberg, D. Schindler

Research output: Chapter in Book/Report/Conference proceedingChapter

4 Citations (Scopus)

Abstract

One out of four to five patients with Fanconi anemia experience a reversion or attenuation of their constitutional mutations during their lifetime. If the reversion event takes place in a bone marrow stem cell or in an early precursor cell of hematopoiesis, peripheral blood cell counts may gradually recover, leading to improved quality of life. At the beginning of this process, MMC testing will reveal a mixture of MMC sensitive and MMC resistant blood lymphocytes, but after several years MMC sensitive cells (the original FA-cells) may be completely replaced by the progeny of the reverted progenitor cell such that the confirmation of FA requires testing of patient fibroblasts. Molecular analysis reveals the presence of the disease causing biallelic mutations in fibroblast-derived DNA whereas MMC-resistant blood cells show only a single defective allele, explaining their phenotypic reversion. The mechanisms leading to revertant mosaicism include intragenic mitotic recombination (crossing over and gene conversion), back mutation, and compensatory second site mutations. Evidence for each of these mechanisms has been obtained in mosaic FA-patients, but their molecular details are not fully understood. Compound heterozygosity facilitates some of these mechanisms, but reversions have also been observed in homozygous patients. Patients belonging to subtypes FA-A, FA-C, FA-D1, FA-D2 and FA-L have developed revertant mosaicism, with subtypes FA-A and FA-D2 being most frequently involved. Even though the phenomenon of revertant mosaicism has been well documented in FA, there still are many questions: we do not know whether the progeny of a single reverted blood stem or progenitor cell would be able to sustain lifelong hematopoiesis, whether revertant mosaicism provides protection against hematopoietic malignancy, or whether it would be possible to deliberately increase the rate of somatic reversions in order to improve chances for 'natural gene therapy'. Prospective and long-term follow-up studies are needed to answer these questions.

Original languageEnglish (US)
Title of host publicationMonographs in Human Genetics
Pages149-172
Number of pages24
Volume15
DOIs
StatePublished - 2007
Externally publishedYes

Publication series

NameMonographs in Human Genetics
Volume15
ISSN (Print)00770876
ISSN (Electronic)16623835

Fingerprint

Fanconi Anemia
Mosaicism
Genetic Therapy
Stem Cells
Mutation
Hematopoiesis
Blood Cells
Fibroblasts
Gene Conversion
Blood Cell Count
Hematologic Neoplasms
Bone Marrow Cells
Genetic Recombination
Alleles
Quality of Life
Lymphocytes
DNA

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Hoehn, H., Kalb, R., Neveling, K., Friedl, R., Bechtold, A., Herterich, S., ... Schindler, D. (2007). Revertant mosaicism in fanconi anemia: Natural gene therapy at work. In Monographs in Human Genetics (Vol. 15, pp. 149-172). (Monographs in Human Genetics; Vol. 15). https://doi.org/10.1159/000102554

Revertant mosaicism in fanconi anemia : Natural gene therapy at work. / Hoehn, H.; Kalb, R.; Neveling, K.; Friedl, R.; Bechtold, A.; Herterich, S.; Sun, Y.; Gruhn, B.; Hanenberg, H.; Schindler, D.

Monographs in Human Genetics. Vol. 15 2007. p. 149-172 (Monographs in Human Genetics; Vol. 15).

Research output: Chapter in Book/Report/Conference proceedingChapter

Hoehn, H, Kalb, R, Neveling, K, Friedl, R, Bechtold, A, Herterich, S, Sun, Y, Gruhn, B, Hanenberg, H & Schindler, D 2007, Revertant mosaicism in fanconi anemia: Natural gene therapy at work. in Monographs in Human Genetics. vol. 15, Monographs in Human Genetics, vol. 15, pp. 149-172. https://doi.org/10.1159/000102554
Hoehn H, Kalb R, Neveling K, Friedl R, Bechtold A, Herterich S et al. Revertant mosaicism in fanconi anemia: Natural gene therapy at work. In Monographs in Human Genetics. Vol. 15. 2007. p. 149-172. (Monographs in Human Genetics). https://doi.org/10.1159/000102554
Hoehn, H. ; Kalb, R. ; Neveling, K. ; Friedl, R. ; Bechtold, A. ; Herterich, S. ; Sun, Y. ; Gruhn, B. ; Hanenberg, H. ; Schindler, D. / Revertant mosaicism in fanconi anemia : Natural gene therapy at work. Monographs in Human Genetics. Vol. 15 2007. pp. 149-172 (Monographs in Human Genetics).
@inbook{5518884b43ad4da980c72673c1a5e170,
title = "Revertant mosaicism in fanconi anemia: Natural gene therapy at work",
abstract = "One out of four to five patients with Fanconi anemia experience a reversion or attenuation of their constitutional mutations during their lifetime. If the reversion event takes place in a bone marrow stem cell or in an early precursor cell of hematopoiesis, peripheral blood cell counts may gradually recover, leading to improved quality of life. At the beginning of this process, MMC testing will reveal a mixture of MMC sensitive and MMC resistant blood lymphocytes, but after several years MMC sensitive cells (the original FA-cells) may be completely replaced by the progeny of the reverted progenitor cell such that the confirmation of FA requires testing of patient fibroblasts. Molecular analysis reveals the presence of the disease causing biallelic mutations in fibroblast-derived DNA whereas MMC-resistant blood cells show only a single defective allele, explaining their phenotypic reversion. The mechanisms leading to revertant mosaicism include intragenic mitotic recombination (crossing over and gene conversion), back mutation, and compensatory second site mutations. Evidence for each of these mechanisms has been obtained in mosaic FA-patients, but their molecular details are not fully understood. Compound heterozygosity facilitates some of these mechanisms, but reversions have also been observed in homozygous patients. Patients belonging to subtypes FA-A, FA-C, FA-D1, FA-D2 and FA-L have developed revertant mosaicism, with subtypes FA-A and FA-D2 being most frequently involved. Even though the phenomenon of revertant mosaicism has been well documented in FA, there still are many questions: we do not know whether the progeny of a single reverted blood stem or progenitor cell would be able to sustain lifelong hematopoiesis, whether revertant mosaicism provides protection against hematopoietic malignancy, or whether it would be possible to deliberately increase the rate of somatic reversions in order to improve chances for 'natural gene therapy'. Prospective and long-term follow-up studies are needed to answer these questions.",
author = "H. Hoehn and R. Kalb and K. Neveling and R. Friedl and A. Bechtold and S. Herterich and Y. Sun and B. Gruhn and H. Hanenberg and D. Schindler",
year = "2007",
doi = "10.1159/000102554",
language = "English (US)",
isbn = "9783805582773",
volume = "15",
series = "Monographs in Human Genetics",
pages = "149--172",
booktitle = "Monographs in Human Genetics",

}

TY - CHAP

T1 - Revertant mosaicism in fanconi anemia

T2 - Natural gene therapy at work

AU - Hoehn, H.

AU - Kalb, R.

AU - Neveling, K.

AU - Friedl, R.

AU - Bechtold, A.

AU - Herterich, S.

AU - Sun, Y.

AU - Gruhn, B.

AU - Hanenberg, H.

AU - Schindler, D.

PY - 2007

Y1 - 2007

N2 - One out of four to five patients with Fanconi anemia experience a reversion or attenuation of their constitutional mutations during their lifetime. If the reversion event takes place in a bone marrow stem cell or in an early precursor cell of hematopoiesis, peripheral blood cell counts may gradually recover, leading to improved quality of life. At the beginning of this process, MMC testing will reveal a mixture of MMC sensitive and MMC resistant blood lymphocytes, but after several years MMC sensitive cells (the original FA-cells) may be completely replaced by the progeny of the reverted progenitor cell such that the confirmation of FA requires testing of patient fibroblasts. Molecular analysis reveals the presence of the disease causing biallelic mutations in fibroblast-derived DNA whereas MMC-resistant blood cells show only a single defective allele, explaining their phenotypic reversion. The mechanisms leading to revertant mosaicism include intragenic mitotic recombination (crossing over and gene conversion), back mutation, and compensatory second site mutations. Evidence for each of these mechanisms has been obtained in mosaic FA-patients, but their molecular details are not fully understood. Compound heterozygosity facilitates some of these mechanisms, but reversions have also been observed in homozygous patients. Patients belonging to subtypes FA-A, FA-C, FA-D1, FA-D2 and FA-L have developed revertant mosaicism, with subtypes FA-A and FA-D2 being most frequently involved. Even though the phenomenon of revertant mosaicism has been well documented in FA, there still are many questions: we do not know whether the progeny of a single reverted blood stem or progenitor cell would be able to sustain lifelong hematopoiesis, whether revertant mosaicism provides protection against hematopoietic malignancy, or whether it would be possible to deliberately increase the rate of somatic reversions in order to improve chances for 'natural gene therapy'. Prospective and long-term follow-up studies are needed to answer these questions.

AB - One out of four to five patients with Fanconi anemia experience a reversion or attenuation of their constitutional mutations during their lifetime. If the reversion event takes place in a bone marrow stem cell or in an early precursor cell of hematopoiesis, peripheral blood cell counts may gradually recover, leading to improved quality of life. At the beginning of this process, MMC testing will reveal a mixture of MMC sensitive and MMC resistant blood lymphocytes, but after several years MMC sensitive cells (the original FA-cells) may be completely replaced by the progeny of the reverted progenitor cell such that the confirmation of FA requires testing of patient fibroblasts. Molecular analysis reveals the presence of the disease causing biallelic mutations in fibroblast-derived DNA whereas MMC-resistant blood cells show only a single defective allele, explaining their phenotypic reversion. The mechanisms leading to revertant mosaicism include intragenic mitotic recombination (crossing over and gene conversion), back mutation, and compensatory second site mutations. Evidence for each of these mechanisms has been obtained in mosaic FA-patients, but their molecular details are not fully understood. Compound heterozygosity facilitates some of these mechanisms, but reversions have also been observed in homozygous patients. Patients belonging to subtypes FA-A, FA-C, FA-D1, FA-D2 and FA-L have developed revertant mosaicism, with subtypes FA-A and FA-D2 being most frequently involved. Even though the phenomenon of revertant mosaicism has been well documented in FA, there still are many questions: we do not know whether the progeny of a single reverted blood stem or progenitor cell would be able to sustain lifelong hematopoiesis, whether revertant mosaicism provides protection against hematopoietic malignancy, or whether it would be possible to deliberately increase the rate of somatic reversions in order to improve chances for 'natural gene therapy'. Prospective and long-term follow-up studies are needed to answer these questions.

UR - http://www.scopus.com/inward/record.url?scp=84870210537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870210537&partnerID=8YFLogxK

U2 - 10.1159/000102554

DO - 10.1159/000102554

M3 - Chapter

SN - 9783805582773

VL - 15

T3 - Monographs in Human Genetics

SP - 149

EP - 172

BT - Monographs in Human Genetics

ER -